Better MRSA Strategy: Treat All ICU Patients
This study, he said in an interview, should change practice. 'This study shows that testing people for MRSA and isolating them is not an effective way to control MRSA in the hospital, which we've been arguing all along."
In an interview, however, Edmond said he is "a little worried, because I think that widespread use of mupirocin will likely lead to development of a lot of resistance." His hospital uses routine chlorhexidine baths in the ICU, but not mupirocin.
MRSA colonization is a major target in quality measurement because bloodstream infections are common and are lethal in more than 20% of cases. Increased length of stay can add costs of as much as $30,000 per patient.
A decade ago, the CDC estimated 90,000 invasive MRSA infections, most of them acquired in hospitals, with 19,000 deaths per year. Hand hygiene and other strategies have reduced those rates by 28% between 2005 and 2008 and again 28% in 2011.
Cheryl Clark is senior quality editor and California correspondent for HealthLeaders Media. She is a member of the Association of Health Care Journalists.
- Readmissions: No Quick Fix to Costly Hospital Challenge
- Ebola: Health Officials Try to Quell Front Line Fears
- How Telehealth Pays Off for Providers, Patients
- Reducing Readmissions Starts with Better Collaboration
- Defensive Medicine Still Prevalent Despite Tort Reform
- 'Overtreatment' Debate Circles Back to Lung Cancer Screening
- Partners HealthCare M&A Deal Under Scrutiny
- How Educated Nurses Save Money
- Ebola: A New Normal in Dallas
- House Calls Key to Pioneer ACO Success